This article was originally published in The Tan Sheet
Woodcock: FDA maintains NSURE focus; J&J rebrands to regain consumer trust; Symrise AG gains research loan; most allergy sufferers take two or more meds, Teva-funded survey finds; Mead Johnson’s Nutramigen LGG reduces milk allergies; more news In Brief.
You may also be interested in...
The domestic OTC/nutritionals business grew more than 14% in the first quarter on the strength of McNeil products returning to market and a severe cold and flu season. Johnson & Johnson’s consumer performance exceeded some market analyst estimates.
Chad Reynolds of RMQ+ spoke to Medtech Insight about practical strategies for managing economic operators efficiently and with a view to long-term compliance.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.